SEATTLE, July 09, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the U.S. liposomal doxorubicin market is estimated to be valued at US$ 140.0 Million in 2020 and is expected to exhibit a CAGR of 4.7% over the forecast period (2020-2027).
Key Trends and Analysis of the U.S. liposomal doxorubicin market:
The key players operating in the market are focusing on increasing approvals of generic liposomal doxorubicin products, which is expected to drive the market growth over the forecast period. For instance, in 2020, Zydus Cadila received the U.S Food and Drug Administration’s approval to market Doxorubicin Hydrochloride Liposome injection (US RLD: Doxil Liposome Injection) in the strengths of 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) single-dose vials.
Furthermore, increasing import of liposomal doxorubicin is expected to assist the growth of the market. For instance, according to the parenteral drug Association 2017, in the U.S., 40% of all liposomal doxorubicin generics are imported from countries such as India and 80% of the active ingredients used in both generic and branded medications is imported from countries such as China and India.
Request for Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/4508
Key Market Takeaways:
The U.S. liposomal doxorubicin market is expected to exhibit a CAGR of 4.7% during the forecast period, owing to increasing approvals of generic liposomal doxorubicin products. For instance, in February 2013, Sun Pharmaceutical Industries Ltd. received the U.S. Food Drug and Administration approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCl Liposome Injection USP, 2mg/mL, packaged in 20 mg/10mL and 50 mg/25mL single-use vials. Doxurubin HCL injection is used to treat multiple myeloma, AIDS-related Kaposi's sarcoma, and ovarian cancer.
Among states, California is estimated to be valued at US$ 16.3 Million in 2020, and is expected to exhibit a CAGR of 75.6% and reach US$ 23.8 Million by 2027. The increasing prevalence of breast cancer in the state of California is expected to drive the market growth. For instance, according to the National Cancer Institute, in 2017, around 401,100 cases of breast cancer (female) was registered in California.
Key companies Covered:
Key players operating in the U.S. liposomal doxorubicin market include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4508
Market Segmentation:
- U.S. Liposomal Doxorubicin Market, By Drug Type:
- Branded
- Generic
- U.S. Liposomal Doxorubicin Market, By Cancer Type:
- Ovarian Cancer
- AIDS-related Kaposi’s Sarcoma
- Multiple Myeloma
- Others
- U.S. Liposomal Doxorubicin Market, By States:
- California
- Texas
- Florida
- New York
- Pennsylvania
- Illinois
- Ohio
- Georgia
- North Carolina
- Michigan
- New Jersey
- Virginia
- Washington
- Arizona
- Others
Related Market Intelligence Reports:
Cancer Cell Market, by Cancer Cell Type (Carcinomas, Sarcomas, Leukemia, and Others), by Application (Chemotherapy, Radiation Therapy, Immunotherapy, Hormone Therapy, Targeted Drug Therapy, and Others), by End User (Hospitals & Clinics, Specialty Clinics, and Diagnostic Laboratories), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
Read more: https://www.coherentmarketinsights.com/market-insight/cancer-cell-market-4338
Interventional Oncology Ablation Market, by Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, and Irreversible Electroporation Ablation), by Indication (Liver Cancer, Kidney Cancer, Lung Cancer, and Others), by End User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 – 2027
Read more: https://www.coherentmarketinsights.com/market-insight/interventional-oncology-ablation-market-4445
Lung Cancer Diagnostic and Screening Market, by Test Type (Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test, Others), Imaging Test ( Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy (Needle Biopsy, Bronchoscopy Biopsy, Open Biopsy, Others), By Cancer Type (Non-small cell lung cancer and Small Cell Lung Cancer), by End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 – 2028
Therapeutic Proteins and Oral Vaccines Market, by Drug Class (Therapeutic Proteins (Growth Factors, Fusion Proteins, Monoclonal Antibodies, Hormones, Coagulation Factors, and Others) and Oral Vaccines (Live Attenuated Vaccine, Inactivated Vaccine, Recombinant Vaccine, and Others), by Application (Oncology, Hematology, Immunology, Endocrinology, Infectious Disease, Cardiovascular Disease, and Others), by Distribution Channel Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com